TRDA
Entrada Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$7.13
−0.56%Margins
Gross margin
-754.7%
EBITDA margin
-3518.3%
EBIT margin
-3767.1%
Net margin
-3537.7%
FCF margin
-2867.1%
-71.0%
Return on equity
-55.5%
Return on assets
-62.6%
Return on invested capital
0.01x
Asset turnover
-$134.7M
Cash from operations
$5.73
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026